1. Scrip

EU First To Approve Novartis’s Cholesterol Drug Leqvio

Twice Yearly Dosing Is Key Selling Point

 
• By Andrew McConaghie

Novartis hopes its new RNAi-based therapy will be a blockbuster – but must eventually show it can cut heart attacks and cardiovascular deaths.

Novartis_Building
Novartis is banking on Leqvio becoming a cardiovascular blockbuster.

The European Commission has granted approval to Novartis’s novel cholesterol treatment inclisiran, under the brand name Leqvio.

A first-in-class small interfering RNA (siRNA) treatment that targets PCSK9, the treatment is now approved for use in adults with hypercholesterolemia or mixed dyslipidemia, and is one

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.